Document is current
Any future updates will be listed below
-
Authors
Verheijden, Simon
Conceição-Neto, Nádia
Bourgeois, Stefan
Vandamme, Céline
Troyer, Ewoud de
Kanoulas, Evangelos
Maeyer, Dries De
Crabbe, Marjolein
Makariadou, Elli
Slaets, Leen
Fevery, Bart
Remoortere, Pieter Van
Biermer, Michael
Kennedy, Patrick T. F.
De Creus, An
- License Information
-
More Information
Article History
Received: 2 June 2025
Accepted: 25 December 2025
First Online: 5 February 2026
Competing interests
: S.B. advisor and speaker for AbbVie, Gilead, Bristol Myers Squibb, and Janssen; P.T.F.K. received grants and/or contracts from Aligos and Vir Biotechnology; received consulting fees from Assembly Bio, Bluejay Therapeutics, GlaxoSmithKline, and Gilead Sciences; received honoraria from GlaxoSmithKline and Gilead Sciences; and served in leadership roles in the British Viral Hepatitis Group. S.V., N.C.N., C.V., E.D.T., E.K., D.D.M., M.C., E.M., L.S., B.F., P.V.R., M.B., A.D.C. authors are or were at the time of study conduct employees of Johnson & Johnson Innovative Medicine, Research and Development, and may be Johnson & Johnson stockholders.
